As of November 6, 2026, Recursion Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: RXRX); its largest reported holder is BlackRock, with 8.5% on Schedule 13G/A of July 29, 2026, then ARK Invest (7.25%). The largest insider holding is Blake Borgeson, a director, with 6,068,287 shares (0.97% of shares outstanding), per Form 4 of November 4, 2026 (Schedule 13G/A, July 29, 2026).
Is this your company?
About to sign with, pay or invest in Recursion Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Recursion Pharmaceuticals, Inc. a real, registered company?
- Recursion Pharmaceuticals Inc files with the SEC under CIK 1601830 (its SEC filings).
- Its shares are listed under the ticker RXRX on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Salt Lake City, Utah, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under RECURSION PHARMACEUTICALS INC in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Fred Hassan, Chair of the Board (Form 8-K filed 2026-11-02). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names State Street (filed 2026-08-07).
Who are Recursion Pharmaceuticals, Inc.'s owners and officers?
Recursion Pharmaceuticals, Inc.: incorporated in Delaware; business address in Salt Lake City, Utah; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-11-02).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-07 | State Street Corporation | 6.6% |
| Schedule 13G, 2026-07-31 | Vanguard Capital Management | 5.09% |
| Schedule 13G, 2026-07-31 | Vanguard Portfolio Management | 5.97% |
| Schedule 13G/A, 2026-07-29 | Blackrock, Inc. | 8.5% |
| Schedule 13G, 2026-05-12 | State Street Corporation | 5.5% |
| Schedule 13G/A, 2026-04-24 | Blackrock, Inc. | 7.2% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-05 | Baillie Gifford & Co | 4.6% |
| Schedule 13G/A, 2026-02-03 | Ark Investment Management LLC | 7.25% |
| Schedule 13D/A, 2025-12-23 | Mubadala Investment Co Pjsc | 1.4% |
Questions about who owns Recursion Pharmaceuticals, Inc.
Who owns Recursion Pharmaceuticals, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Recursion Pharmaceuticals, Inc.: Blackrock, Inc. (8.5%, Schedule 13G/A, filed 2026-07-29), Ark Investment Management LLC (7.25%, Schedule 13G/A, filed 2026-02-03), State Street Corporation (6.6%, Schedule 13G, filed 2026-08-07), Vanguard Portfolio Management (5.97%, Schedule 13G, filed 2026-07-31) and Vanguard Capital Management (5.09%, Schedule 13G, filed 2026-07-31).
Who are the largest shareholders of Recursion Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of Recursion Pharmaceuticals, Inc. on this page are Blackrock, Inc. (8.5%), Ark Investment Management LLC (7.25%) and State Street Corporation (6.6%).
When did Blackrock, Inc. buy into Recursion Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-04-24, reporting 7.2%; its latest, Schedule 13G/A filed 2026-07-29, reports 8.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Recursion Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Recursion Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Recursion Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-11-02 | Fred Hassan | Chair of the Board | appointed | |
| Form 8-K, 2026-11-02 | Fred Hassan | appointed |
Which insiders own Recursion Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 6,068,287 shares (0.97% of shares outstanding) (Form 4, 2026-11-04).
- , a director: 3,319,755 shares (0.53% of shares outstanding), 1,476,707 held directly and 1,843,048 indirectly (Form 4, 2026-10-02).
- , the chief executive and president: 2,072,890 shares (0.33% of shares outstanding) (Form 4, 2026-09-10).
- , the chief financial officer: 1,487,694 shares (0.24% of shares outstanding) (Form 4, 2024-11-19).
- , the chief financial officer: 1,071,462 shares (0.17% of shares outstanding) (Form 4, 2026-09-16).
Shares outstanding: 622,759,259 as of 2026-10-26, from the company's latest SEC cover page.
How much has Recursion Pharmaceuticals, Inc. raised?
No fundraising or offering filing from Recursion Pharmaceuticals, Inc. is on file with us.
Keep reading
More on Recursion Pharmaceuticals, Inc. and the records around it.
Recursion Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Leadership changes Apr 2026
Companies that share a holder
- Mubadala Investment Co PJSC also filed stake reports on 5 other companies: Evotec SE (Oct 2026), GLOBALFOUNDRIES Inc. (Aug 2026), Blue Owl Technology Finance Corp. (Feb 2026)
- ARK Investment Management LLC also filed stake reports on 20 other companies: Tempus AI, Inc. (Nov 2026), 10x Genomics, Inc. (Oct 2026), Twist Bioscience Corp (Sep 2026)
- BAILLIE GIFFORD & CO also filed stake reports on 39 other companies: QXO, Inc. (Oct 2026), Reddit, Inc. (Oct 2026), Samsara Inc. (Oct 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/recursion-pharmaceuticals